Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY Putting It's Best Foot Forward

<< Previous

Bullboard Posts

Next >>

Comment by westcoast1000on Mar 14, 2023 7:26pm

181 Views

Post# 35338652

RE:ONCY Putting It's Best Foot Forward

"I think it is now evident that confidentiallity agreements with pharma companies recieving the BRACELET-1 data relates to the specifics of the BRACELET-1 data and the negotiating pharmas. It does not relate to other information or trial results that ONC/Y is free to release or use to promote the company."

I was wondering about this point also. Thanks for clarifying your perspective.

<< Previous

Bullboard Posts

Next >>

Dollar Tree CEO Rick Dreiling steps down as discount retailer struggles